Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
Xiying Ren,Qiusha Huang,Qingyuan Qu,Xuan Cai,Haixia Fu,Xiaodong Mo,Yu Wang,Yawei Zheng,Erlie Jiang,Yishan Ye,Yi Luo,Shaozhen Chen,Ting Yang,Yuanyuan Zhang,Wei Han,Feifei Tang,Wenjian Mo,Shunqing Wang,Fei Li,Daihong Liu,Xiaoying Zhang,Yicheng Zhang,Shuqing Feng,Feng Gao,Hailong Yuan,Dao Wang,Dingming Wan,Huan Chen,Yao Chen,Jingzhi Wang,Yuhong Chen,Ying Wang,Kailin Xu,Tao Lang,Xiaomin Wang,Hongbin Meng,Limin Li,Zhiguo Wang,Yanling Fan,Yingjun Chang,Lanping Xu,Xiaojun Huang,Xiaohui Zhang
DOI: https://doi.org/10.1182/bloodadvances.2021004349
IF: 7.642
2021-11-30
Blood Advances
Abstract:Abstract Intracranial hemorrhage (ICH) is a rare but fatal central nervous system complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, factors that are predictive of early mortality in patients who develop ICH after undergoing allo-HSCT have not been systemically investigated. From January 2008 to June 2020, a total of 70 allo-HSCT patients with an ICH diagnosis formed the derivation cohort. Forty-one allo-HSCT patients with an ICH diagnosis were collected from 12 other medical centers during the same period, and they comprised the external validation cohort. These 2 cohorts were used to develop and validate a grading scale that enables the prediction of 30-day mortality from ICH in all-HSCT patients. Four predictors (lactate dehydrogenase level, albumin level, white blood cell count, and disease status) were retained in the multivariable logistic regression model, and a simplified grading scale (termed the LAWS score) was developed. The LAWS score was adequately calibrated (Hosmer-Lemeshow test, P > .05) in both cohorts. It had good discrimination power in both the derivation cohort (C-statistic, 0.859; 95% confidence interval, 0.776-0.945) and the external validation cohort (C-statistic, 0.795; 95% confidence interval, 0.645-0.945). The LAWS score is the first scoring system capable of predicting 30-day mortality from ICH in allo-HSCT patients. It showed good performance in identifying allo-HSCT patients at increased risk of early mortality after ICH diagnosis. We anticipate that it would help risk stratify allo-HSCT patients with ICH and facilitate future studies on developing individualized and novel interventions for patients within different LAWS risk groups.
hematology